Zolmitriptan-induced acute myocardial infarction by Kocaoglu, Ibrahim et al.
CASE REPORT
Cardiology Journal
2012, Vol. 19, No. 1, pp. 76–78
10.5603/CJ.2012.0011
Copyright © 2012 Via Medica
ISSN 1897–5593
76 www.cardiologyjournal.org
ç
i
ç
Address for correspondence: Ibrahim Kocaoglu, MD, Ankara Numune Education and Research Hospital, Department
of Cardiology, Talatpasa Bulvari, 06100, Sihhiye, Ankara, Turkey, tel: 009 050 671 581 38, fax: 009 031 231 143 40,
e-mail: koroner80@gmail.com
Received: 17.05.2010 Accepted: 20.07.2010
Zolmitriptan-induced acute myocardial infarction
Ibrahim Kocaoglu, Serkan Gökaslan, Ahmet Karagöz,
Deniz Sahin, Özgül Ucar, Sinan Aydogdu
Ankara Numune Education and Research Hospital, Department of Cardiology,
Talatpasa Bulvari, Sihhiye, Ankara, Turkey
Abstract
Triptans are an established treatment for acute migraine attacks. By activating 5HT1B/1D
receptors they lead to vasoconstriction of the cerebral blood vessels which are dilated during
migraine attacks. Moreover, they reduce secretion of vasoactive peptides and conduction of
pain stimuli over the cerebral cortex. In up to 7% of cases of treatment with triptans, thoracic
pain occurs, although this is mostly transient, mild and without lasting ischemia. We present
the case of a 45 year-old woman with a history of migraine with visual aura since the age of
20. She had no history of diabetes mellitus, hypertension, smoking or any other risk factors for
cardiovascular events before she was admitted to our emergency room with typical chest pain.
An electrocardiogram revealed anterior myocardial infarction following her monthly dose of
oral zolmitriptan. Catherization revealed a normal coronary arterial system. The laboratory
indices for cardiac risk were within normal ranges. The patient was advised to avoid triptans
permanently on being discharged. (Cardiol J 2012; 19, 1: 76–78)
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Introduction
Triptans are an established treatment for acute
migraine attacks. By activating 5HT1B/1D-recep-
tors they lead to vasoconstriction of the cerebral
blood vessels which are dilated during migraine
attacks [1]. Moreover, they reduce secretion of
vasoactive peptides and conduction of pain stimuli
over the cerebral cortex [1]. Although triptans ex-
ert their therapeutic effect through cerebral vaso-
constriction, studies have also documented vaso-
constriction in the coronary, pulmonary, and sys-
temic vasculature [2]. In up to 7% of cases of
treatment with triptans, thoracic pain occurs, al-
though this isusually transient, mild and without last-
ing ischemia. The incidence of myocardial infarction
under triptans is estimated to be very low [3]. Most
published case reports refer to myocardial infarction
after the use of sumatriptan (subcutaneous [4, 5] oral
[6–8] and nasal [9] application), whereas both ste-
notic [5, 8] and normal [6–9] coronary arteries could
be found angiographically. Besides sumatriptan,
acute coronary syndrome has been described after
the use of zolmitriptan [10–12] and frovatriptan [13].
The mechanism for these events is thought to be
related to vasoconstriction superimposed on a pre-
existing coronary lesion [14]. However, these side
effects can also be seen in patients with angiogra-
phically normal coronary arteries.
Case report
This 45 year-old woman had a history of mi-
graine with visual aura since she was 20. She aver-
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aged one or two attacks per week and had been tak-
ing zolmitriptan for six years. On the day of admis-
sion, the patient had experienced a typical migraine
attack and had taken 5 mg of zolmitriptan. Four
hours later, she had a sudden onset chest pain,
which she described as pressure localized to the
retrosternal area. She repeated the same dose of
zolmitriptan for cephalgia, while she was still hav-
ing chest pain. She presented to the emergency
room with ongoing chest pain, and a 12-lead elec-
trocardiogram revealed ST-segment elevation in
anterior precordial leads (Fig. 1). She had no histo-
ry of diabetes mellitus, hypertension, smoking or
other risk factors for cardiovascular events. She was
admitted to the coronary care unit and a cardiac
catheterization and additional laboratory studies
were performed the following day. The catheriza-
tion revealed a normal coronary arterial system
(Figs. 2, 3). Laboratory indices for cardiac risk were
within normal ranges. Cardiac enzymes and tropo-
nin-I were elevated. In her transthoracic echocar-
diogram, hypokinesia in the left ventricular anterior
wall and apical part of the interventricular septum
were reported, with an ejection fraction of 52%. The
patient was given an angiotensin converting enzyme
blocker and was advised to avoid triptans perma-
nently when she was discharged. A control echocar-
diogram performed two months later revealed sim-
ilar findings to that of the pre-discharge echo-
cardiogram.
Discussion
Zolmitriptan, a 5HT1 agonist, belongs to a class
of anti-migraine drugs that are known to cause va-
soconstriction, precipitating chest pain in a signifi-
cant proportion of patients, but rarely causing seri-
ous cardiovascular events. Zolmitriptan is an anti-
migraine medication that shows its effect on the
5-hydroxytryptamine (5-HT) serotonin receptor. At
first, this class of drugs was thought to affect sole-
ly cerebral vasculature by causing vasoconstriction.
However, due to the presence of other 5-HT1-type
receptors in coronary arteries, or varying degrees
of receptor reactivities of these drugs, vasoconstric-
tion on the coronary circulation has been seen and
Figure 1. The electrocardiogram of the patient during
her admission to the coronary care unit.
Figure 3. Normal right coronary artery on coronary
angiogram.
Figure 2. Normal coronary arteries in RAO caudal posi-
tion in the coronary angiography.
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has been widely documented in-vivo and in-vitro [2].
While almost all previously reported myocardial
infarction, which were thought to be secondary to
triptan use have occurred after administration of su-
matriptan, recent reports involving tegaserod and
zolmitriptan point to a possible class effect for these
anti-migraine medications. This class effect is to be
expected, as zolmitriptan has a similar mechanism
of action as other triptans [14]. As mentioned pre-
viously, most cases reported have involved the use
of sumatriptan. Hadjiloizou et al.  [13] published
a case of fravotriptan as a probable cause of vaso-
constriction. Weder et al. [15] described for the first
time an acute coronary syndrome in a 67 year-old
female patient after oral intake of 2.5 mg naratriptan
for migraine. Similarly to our case, three other cas-
es of acute coronary syndrome with zolmitriptan
have been reported [10–12], with one of the three-
-patients in question using zolmitriptan and citalo-
pram concurrently.
To the best of our knowledge, our report rep-
resents the fourth case of acute coronary syndrome
related to zolmitriptan. Normal coronary arteries
were shown angiographically, so a vasospastic
mechanism was considered. Although mostly seen
in diseased coronary arteries, this side effect of
triptans can also be recognized in normal coronary
arteries. Our patient was advised to avoid triptans,
but they can be the only course of treatment for
some migraine patients. As pointed out by Evans
et al. [14], physicians should attempt to use other
abortive therapies in migraine patients with any
cardiovascular risk factors. In those patients for
whom no other effective options exist for migraine
therapy, specific counseling regarding symptoms of
myocardial ischemia should be given by physicians
when prescribing these medications.
Conflict of interest: none declared
References
1. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine:
A comparative review of pharmacology, pharmacokinetics and
efficacy. Drugs, 2000; 60: 1259–1287.
2. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS.
Effect of subcutaneous sumatriptan, a selective 5HT1 agonist
on the systemic, pulmonary, and coronary circulation. Circula-
tion, 1993; 87: 401–405.
3. Dodick D, Lipton RB, Martin V et al. Triptan Cardiovascular
Safety Expert Panel Consensus Statement: Cardiovascular safe-
ty profile of triptans (5HT1B/1D-agonists) in the acute treat-
ment of migraine. Headache, 2004; 44: 414–425.
4. Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH. Trans-
mural myocardial infarction with sumatriptan. Lancet, 1993; 341:
861–862.
5. Anghileri E, Toso V, Perini F. Acute myocardial infarction after
sumatriptan administration for cluster headache. Neurol Sci,
2006; 26: 456–459.
6. Weir RA, Oldroyd KG, Walters MR. Myocardial infarction after
oral sumatriptan use in a woman with normal coronary arteries.
Am J Med, 2007; 120: e7–e8.
7. O’Connor P, Gladstone P. Oral sumatriptan-associated transmural
myocardial infarction. Neurology 1995; 45: 2274–2276.
8. Hack JB. Oral sumatriptan-induced myocardial infarction. J To-
xicol Clin Toxicol, 2004; 42: 309–311.
9. Erbilen E, Ozhan H, Akdemir R, Yazici M. A case of myocardial
infarction with sumatriptan use. Pediatr Cardiol, 2005; 26:
464–466.
10. Pacheco-Coronado R, McMullan PW, Galbut BH, Galbut EJ,
Snell J, Schaer GL, Kavinsky CJ. Myocardial infarction after
taking zolmitriptan. Yale J Biol Med, 2005; 78: 147–150.
11. Mikhail GW, Airoldi F, Colombo A. Acute myocardial infarction
following the use of antimigraine therapy. J Invasive Cardiol,
2004; 16: 602–603.
12. Acikel S, Dogan M, Sari M, Kilic H, Akdemir R. Prinzmetal-
-variant angina in a patient using zolmitriptan and citalopram.
Am J Emerg Med, 2010; 28: 257.e3–257.e6.
13. Hadjiloizou N, Rakhit R. Frovatriptan, a probable cause of coro-
nary vasoconstriction. Int J Clin Pract, 2008; 62: 1121–1122.
14. Evans RW, Martin V. Assessing cardiac risk prior to use of
triptans. Headache, 2000; 40: 599–602.
15. Weder CR, Schneemann M. Triptans and troponin: A case
report. Orphanet J Rare Dis, 2009; 4: 15.
